Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: July 15, 2025
Reporting Period: Specific event date of July 15, 2025
Business Overview: The Company is a Delaware corporation focused on developing diagnostic technologies, specifically utilizing flow cytometry for lung cancer detection.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the receipt of a patent allowance from the China National Intellectual Property Administration (CNIPA). This represents a significant milestone in the Company's intellectual property portfolio regarding its lung cancer detection technology.
Guidance, Outlook, and Management Commentary
- Patent Allowance: On July 15, 2025, the Company announced the allowance of a patent application titled "System and Method for Determining Lung Health."
- Technology Scope: The patent protects methods for predicting the likelihood of lung cancer using flow cytometry. It specifically covers the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum to determine the presence of lung cancer cells.
- Management Commentary: No specific financial guidance or forward-looking statements regarding revenue or earnings were included in this filing. The focus is strictly on the intellectual property milestone.
- Risks and Contingencies: No specific risks or contingencies were detailed in this report beyond the standard nature of patent enforcement and commercialization which are implied by the filing.
Investor Verification Checklist
- Verify the commercial viability and timeline for bringing the "System and Method for Determining Lung Health" technology to market in China.
- Confirm the scope of the patent protection to ensure it covers the specific antibodies and TCPP porphyrin methods described.
- Review the attached Press Release (Exhibit 99.1) for any additional details on the regulatory pathway or partnership opportunities related to this patent.
- Check subsequent filings for any financial impact or capital requirements associated with commercializing this new patent.